Applied Autonomy AS er et innovativt selskap som utvikler kontrollsystemer og tjenester for sikker innføring og drift av fremtidens autonome transportsystemer. Vi leverer kunnskap, løsninger og tjenester for autonom transport og gjennomfører demonstrasjoner, piloter og utprøving av autonome kjøretøy. Vi er et ungt firma med høy kompetanse og gode nasjonale og internasjonale nettverk. Vi er en troverdig partner for både offentlige og private aktører når det gjelder framtidens transportløsninger. Vi holder til i teknologibyen Kongsberg, hvor vi sammen med våre partnere tester ulike teknologier og use-caser. Vi er fremoverlente og er ikke redde for å prøve ut nye løsninger.

We improve the way the shipping industry works and communicates. The whole industry is currently bogged down with unstructured emails and ship data.We have built a great ship database, and have a growing and happy customer base just from this. But we are not done. We are building communication tools on top of this, massively increasing the number of users we can help out!

Apotek 1 er Norges største apotekkjede og vi er i stadig vekst. Hos oss jobber ca. 3500 dedikerte medarbeidere, og vi er også landets største farmasøytiske arbeidsgiver. Vi har en stolt kultur med klare ambisjoner om alltid å leve opp til vårt slagord 'Vår kunnskap - din trygghet' i våre kundemøter. Kompetanse og kvalitet er kjernen for vår virksomhet, og derfor er faglig og personlig videreutvikling av våre medarbeidere helt sentralt i kjeden. I Apotek 1 er vi opptatt av å etterleve våre verdier som er: pålitelig, frisk, engasjert og nær. Vi bestreber at dette skal prege alle ansatte, alle beslutninger, alle handlinger og alle mål i selskapet. Apotek 1 Gruppen AS er eiet av den tyske Phoenix-gruppen. Servicekontor og distribusjonsenhet ligger på Lørenskog i Akershus. Vi er landets største leverandør av legemidler pakket i multidose, samt legemidler og tjenester til kommunehelsetjenesten, blant annet legemiddelgjennomganger.

Fjelltopp Media's main focus lies in the development of our main product Byndle. Byndle gathers data from over 30 different Norwegian data sources and bundles them together. This is then served to our customers via a user-friendly interface, which leads to businesses having the opportunity to make data-driven decisions. Byndle is our main product, and it was launched in late 2019. We are now looking for people to help us grow into new areas and continue making this an even greater product. We have many concepts in the loop, and a good client base to work with, as well as a widespread team to help us reach our goals. We are seeking new development-driven tech enthusiasts that want to take part in our journey.

Xfrakt er et innovativt selskap som tenker på fremtiden. Vi er en tjeneste som er lett å forstå og lettere å bruke. Det er veldig viktig for oss å ha god fremtoning med alle kunder på begge parter av leveransen. Vi har stort fokus på god service og godt miljø, både på kontoret og på veien. Xfrakt er 100% elektrisk innenfor Oslo/Lysaker/Drammen/Gardermoen/Ski. Vi er et firma som tenker nytt, vi startet vårt første budbilselskap i 1977 og har dermed 40 år med erfaring. Nå ser vi etter å revolusjonere det vi i dag kaller transport!Xfrakt skal være den beste budbiltjenesten i Norge!Xfrakt gir deg ikke følelsen av et vanlig budbil firma, Xfrakt er eksklusive, Xfrakt er effektive, Xfrakt er enkelt og Xfrakt funker.Det viktigste av alt, Xfrakt er DITT grønne skifte.

HTTECH's mission is to support heavy industries on the way to sustainable development. HTTECH's vision: Contribute to solving environmental challenges for the established industry in a cost-efficient manner and produce nano-based materials for the future to transform waste into high-value products with high-demand. Build sustainable business in the space of circular economyHTTECH is a company with a solid competence in the field of high-temperature technologiesExpertise: R&D projects in the fields of Hydrogen and Solar Energetics, Energy Savings, Oil&Gas Industry, Computer ModelingMetallurgy & Chemical Engineering, Materials Science and International Business Development Industrial expertise

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

An intracellular approach to diagnostics – changing the way diagnostics approach blood tests. Pre Diagnostics is the first diagnostics company to focus on intracellular measurements of disease-specific biomarkers inside the blood cells. We extract disease-relevant information from biomarkers located inside specific blood cells called monocytes to provide actionable results for patients and practitioners.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Gruten is an Oslo-based company that creates new value and meaning from coffee waste. We use coffee grounds in the production of soap and body scrub, and run an educational program with lectures, courses, and workshops to create awareness and knowledge about coffee grounds as a valuable resource.  We have a small production/workshop/outlet at Torshov, and sell our products on our own webshop + in ca 35 stores around Oslo and the rest of Norway. At the moment we are working hard to set up a site for mushroom production, growing oyster mushrooms on coffee grounds. When we get a go-ahead for this we will be in demand for funding to set up the production site (we will be growing in used cooling containers, so-called reefers) and need people to work on the site.

AURA Biopharm AS was founded in 2016 by a team of scientists and drug developers with many years of experience in academia and major pharmaceutical companies and a proven track record of success in drug development. The emphasis of AURA is the development of novel and breakthrough therapies for unmet medical needs and orphan diseases and our slogan “A new opportunity for health” reflects AURA's mission to give a new opportunity to diseases in need of new and/or better therapies. The company operates virtually using a network of external collaborators (consultants, KOLs, CROs, CMOs etc).

We are disrupting heavy construction. They build roads and infrastructure for billions of NOK/USD/EUR. But paper and old-school applications are still the things when it comes to data collection and reporting. We have cracked some of the code and have landed contracts with some of the biggest construction companies in the world. Are you the kind of person that would like to join a startup in the beginning? Take charge of your field, and help us become the global leader that we have the potential to be. All that stands between us and international success is us - and you. Can we execute well enough? We have a base product. The market has already accepted us. Do you want to join the core team? Reach out to us! We are especially on the lookout for the following areas. But please reach out if you think you have anything of value to us! - UX / front-end (future stack is react-based, you will help us mold it) - Native gurus (iOS/Android)

David Strømman Nedal (born 1 march 1986) is a Norwegian fashion designer. He is the head of the Norwegian luxury suit brand Julius Caesar. Julius Caesar is a luxury private suit label that specializes in high-net customers with limited time and high demands. David is often used in the national press, both TV and print giving his advice on how to dress.

AYR AS er bygget opp av to avdelinger, henholdsvis Kommunikasjon og Infrastruktur.Kommunikasjon leverer ytelsesbaserte kommunikasjonstjenester og markedsføring. Vi har derfor et stort fokus på det digitale. I Infrastrukturavdelingen leverer vi de tradisjonelle IT-tjenestene men den grunnleggende idéen er at vi skal bruke den nye teknologien, herunder skyteknologi. Vi ønsker å gjøre IT enkelt og kombinert med at tjenestene vi leverer er tett knyttet til hverandre – gir det kundene ett kontaktpunkt. Teknologi kan både påvirke samfunnet og miljøet. Alle som jobber i AYR ønsker at teknologisk utvikling skal dytte samfunnet i riktig retning, hvor teknologi gjør at alle kan bidra og bli hørt. Vi bidrar derfor gjennom at 5% av konsernets overskudd fordeles mellom barne- og ungdomsarbeid innenfor teknologi og støttearbeid innen teknologi i utviklingsland.

We deliver production and distribution tools for content in the story format, allowing customers to leverage the format on their own platforms or web pages. Adding stories to your webpage, listing or email is often a lot easier than people think. Most of our users are able to embed stories by simply copying and pasting a snippet.